Alexei Tumanov | Immunology | Innovative Research Award

Published on by Molecular Biologist

Innovative Research Award

Alexei Tumanov
The University of Texas at San Antonio, United States

Alexei Tumanov
Affiliation The University of Texas at San Antonio
Country United States
Google Scholar ID EDMA9agAAAAJ
Documents 97
Citations 7,514
h-index 41
Subject Area Immunology
Event International Molecular Biologist Awards
ORCID 0000-0001-6042-0152
Scopus 35351917100

Alexei Tumanov is an immunology researcher affiliated with the University of Texas at San Antonio and the Department of Microbiology, Immunology and Molecular Genetics at UT Health San Antonio. Institutional and bibliographic sources describe his research in relation to cytokine signaling, lymphotoxin biology, immune regulation, lymphoid-organ biology, inflammation, cancer immunotherapy and neuroimmune mechanisms.[1][2]

Abstract

Alexei Tumanov’s research profile is centered on molecular and cellular immunology, with particular emphasis on lymphotoxin signaling and its relationship to immune-system organization, inflammatory responses and disease mechanisms. His institutional research record includes investigations of lymphotoxin-beta receptor signaling, innate and adaptive immune responses, cancer immunotherapy and neuroimmune interactions.[1] Recent publications have examined lymphotoxin-beta receptor regulation of chronic pain, ferroptosis-associated regulation of innate lymphoid cell responses, and strategies intended to separate antitumor activity from immune-mediated toxicity in CD137-directed cancer immunotherapy.[2][3]

Keywords

  • Immunology
  • Molecular Immunology
  • Lymphotoxin Signaling
  • Lymphotoxin-beta Receptor
  • Cytokine Biology
  • Innate Immunity
  • Cancer Immunotherapy
  • Neuroimmune Regulation
  • Inflammation

Introduction

Molecular immunology examines how signaling pathways, immune-cell interactions and tissue environments regulate protective immunity and inflammatory disease. Within this field, lymphotoxin signaling represents an important area for studying the organization and maintenance of lymphoid tissues and the communication between immune and non-immune cells. Tumanov’s research has addressed these mechanisms through experimental studies of lymphotoxin pathways and their roles in immune-system development and disease-related processes.[1]

His earlier work included conditional targeting studies of lymphotoxin pathways in lymphoid organs. Such research contributed to the characterization of cell-specific functions of lymphotoxin and lymphotoxin-beta receptor signaling in peripheral lymphoid-organ development and maintenance.[4] More recent work has extended this research framework to inflammatory bowel disease, cancer immunotherapy and neuroimmune signaling.[2][3]

Research Profile

Institutional information identifies Tumanov as a researcher in the Department of Microbiology, Immunology and Molecular Genetics at UT Health San Antonio. His documented research interests include immune regulation, cytokine signaling and lymphotoxin biology. His research profile also encompasses interactions between immune pathways and pathological processes, including inflammation, cancer and chronic pain.[1][2]

The research program has included both fundamental and disease-oriented investigations. Earlier studies examined lymphotoxin-dependent organization of lymphoid organs, while later studies have investigated how related signaling mechanisms can influence therapeutic toxicity, inflammatory responses and sensory-neural processes.[4][5]

Research Contributions

A central contribution of Tumanov’s research is the investigation of lymphotoxin-beta receptor signaling as a regulator of immune and tissue processes. Experimental work has examined how this receptor pathway contributes to lymphoid-organ development and maintenance and how alterations in the pathway can affect inflammatory and pathological responses.[4]

In cancer immunotherapy, Tumanov has investigated mechanisms associated with the toxicity of CD137-directed treatment. A Cancer Prevention and Research Institute of Texas grant lists him as principal investigator for a project examining the role of lymphotoxin-beta receptor signaling in overcoming liver toxicity associated with anti-CD137 cancer immunotherapy.[5]

His recent collaborative research has also examined neuroimmune mechanisms. A 2026 Cell Reports publication reported that lymphotoxin-beta receptor signaling is involved in the development of chronic pain, providing experimental evidence connecting an immune signaling pathway with sensory processes.[3]

Additional work published in Cellular & Molecular Immunology examined ferroptosis in relation to ILC2 responses in inflammatory bowel disease. The article identifies lymphotoxin-related immunological research within a broader investigation of inflammatory mechanisms affecting innate lymphoid cells.[2]

Publications

Tumanov’s publication record spans molecular immunology, cytokine signaling, lymphoid-organ biology, inflammatory disease, cancer immunotherapy and neuroimmune regulation. His institutional profile lists publications including recent studies in Science Advances, Cell Reports and Cellular & Molecular Immunology.[1]

  • Tumanov, A. V., et al. (2026). Lymphotoxin-beta receptor controls the development of chronic pain. Cell Reports, 45(4), 117269. DOI: 10.1016/j.celrep.2026.117269.[3]
  • Korchagina, A. A., & Tumanov, A. V. (2026). Ferroptosis shapes ILC2 responses in inflammatory bowel disease. Cellular & Molecular Immunology, 23, 583–585. DOI: 10.1038/s41423-026-01404-z.[2]
  • Shein, S. A., Korchagina, A. A., Wang, L.-J., et al., including Tumanov, A. V. (2026). Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity. Science Advances, 12(17), eaea8737.[1]
  • Tumanov, A. V., et al. (2003). Dissecting the role of lymphotoxin in lymphoid organs by conditional targeting. Immunological Reviews. DOI: 10.1034/j.1600-065X.2003.00071.x.[4]

Research Impact

The documented research program connects fundamental immunological mechanisms with disease-oriented questions. Institutional records describe grant-supported research into the regulation of cancer immunotherapy toxicity and the role of lymphotoxin-beta receptor signaling in sensory neurons, while recent publications extend the research into chronic pain and inflammatory bowel disease.[2][3][5]

The quantitative metrics supplied for this recognition profile list 97 documents, 7,514 citations and an h-index of 41. Such metrics are bibliographic indicators and should be interpreted according to the database, date of retrieval and author-profile methodology used. The supplied Google Scholar, ORCID and Scopus identifiers provide external routes for verification and updating of these records.

The translational relevance of the research is also reflected in grant-supported projects. CPRIT records identify Tumanov as principal investigator of research concerning anti-CD137 cancer immunotherapy and lymphotoxin-beta receptor signaling, illustrating an application-oriented dimension of his immunological research.[5]

Award Suitability

The documented research themes are closely associated with molecular and cellular immunology, including cytokine signaling, lymphotoxin biology, immune-cell regulation and disease mechanisms. His publication record and institutionally documented research projects provide identifiable evidence of sustained activity in these areas.[1][5]

For the purposes of the International Molecular Biologist Awards, the supplied recognition category is the Innovative Research Award. This article records the relationship between the stated award category and the documented research profile without assigning an independent assessment of scientific merit.

Conclusion

Alexei Tumanov’s research profile encompasses molecular immunology, lymphotoxin signaling and the regulation of immune responses in physiological and pathological settings. His documented work includes studies of lymphoid-organ biology, inflammatory disease, cancer immunotherapy and neuroimmune mechanisms. Recent publications demonstrate continuing investigation of lymphotoxin-beta receptor pathways and immune-cell regulation, while grant records document support for translational research involving cancer immunotherapy.[1][2][3][5]

References

  1. UT Health San Antonio. (n.d.). Tumanov, Alexei, M.D., Ph.D. — Microbiology, Immunology & Molecular Genetics. Institutional researcher profile.
    https://lsom.uthscsa.edu/mimg/team-member/alexei-v-tumanov-m-d-ph-d/
  2. Korchagina, A. A., & Tumanov, A. V. (2026). Ferroptosis shapes ILC2 responses in inflammatory bowel disease. Cellular & Molecular Immunology, 23, 583–585. DOI: 10.1038/s41423-026-01404-z.
    https://doi.org/10.1038/s41423-026-01404-z
  3. Tumanov, A. V., Mecklenburg, J. M., Belugin, S., et al. (2026). Lymphotoxin-beta receptor controls the development of chronic pain. Cell Reports, 45(4), 117269. DOI: 10.1016/j.celrep.2026.117269.
    https://doi.org/10.1016/j.celrep.2026.117269
  4. Tumanov, A. V., et al. (2003). Dissecting the role of lymphotoxin in lymphoid organs by conditional targeting. Immunological Reviews. DOI: 10.1034/j.1600-065X.2003.00071.x.
    https://doi.org/10.1034/j.1600-065X.2003.00071.x
  5. Cancer Prevention and Research Institute of Texas. (2022). Grant RP220470: Overcoming liver toxicity of anti-CD137 cancer immunotherapy. Principal Investigator: Alexei Tumanov. University of Texas Health Science Center at San Antonio.
    https://www.cprit.texas.gov/grants-funded/grants/rp220470

georges Bahr | Immunology | Innovative Research Award

Published on by Molecular Biologist

 

Innovative Research Award

              Georges Bahr
Researcher Georges Bahr
Affiliation University of Balamand
Country Lebanon
Scopus ID 7102520346
Documents 116
Citations 2,560
h-index 28
Subject Area Immunology
Event International Molecular Biologist Awards

Georges Bahr

University of Balamand, Lebanon

Georges Bahr is affiliated with the University of Balamand in Lebanon and has an indexed research profile in the field of immunology. The Innovative Research Award recognizes researchers whose scholarly work demonstrates sustained scientific activity, originality, and measurable contribution to their respective fields. According to the supplied Scopus profile information, the researcher has 116 documents, 2,560 citations, and an h-index of 28.[1]

Abstract

Georges Bahr’s academic profile reflects an established research record in immunology, supported by a substantial body of indexed scholarly publications and measurable citation activity. The supplied bibliometric data identify 116 documents, 2,560 citations, and an h-index of 28. These indicators provide quantitative evidence of research visibility and scholarly influence, while qualitative assessment of individual publications remains important when evaluating scientific innovation and significance.[1][2]

Keywords

Immunology, Molecular Biology, Cellular Immunology, Immune Response, Biomedical Research, Scientific Publications, Research Impact, Citation Analysis, Translational Research, Academic Excellence.

Introduction

Immunology is a multidisciplinary area of biomedical science concerned with the study of immune-system components, immune responses, host–pathogen interactions, inflammation, and mechanisms underlying immune-mediated disease. Contemporary immunological research frequently integrates molecular biology, cellular biology, genetics, microbiology, and clinical science to investigate mechanisms operating at multiple biological scales.[3]

Academic research profiles in immunology may be assessed using both qualitative and quantitative measures. Bibliometric indicators, including publication counts, citation counts, and the h-index, can provide useful contextual information regarding scholarly dissemination and influence, although they do not independently establish the scientific quality of individual studies.[2][4]

Research Profile

Georges Bahr is associated with the University of Balamand, Lebanon, and is represented in Scopus under author identifier 7102520346. The supplied profile records 116 documents and 2,560 citations, with an h-index of 28. These figures indicate a sustained publication record and citation presence within the indexed scholarly literature.[1]

  • Institutional affiliation: University of Balamand.
  • Country: Lebanon.
  • Primary subject area: Immunology.
  • Scopus author identifier: 7102520346.
  • Indexed documents: 116.
  • Reported citations: 2,560.
  • Reported h-index: 28.

Research Contributions

Research in immunology contributes to understanding the molecular and cellular mechanisms responsible for immune recognition, regulation, inflammation, host defense, and immune-associated disorders. Within this broad discipline, scholarly contributions can encompass experimental investigation, molecular characterization, cellular studies, disease mechanisms, and translational approaches. The available profile information establishes Georges Bahr’s disciplinary classification but does not provide sufficient evidence to assign specific individual discoveries or mechanisms without reviewing the underlying publications.[1][3]

The combination of publication activity and citation accumulation provides an indication that the researcher’s work has been disseminated within the scholarly literature. Detailed evaluation of originality, methodological rigor, reproducibility, and practical significance should be conducted at the publication level by subject-matter experts.[4]

Publications

The supplied Scopus information records 116 documents associated with Georges Bahr. Scopus provides bibliographic and citation information that can be used to examine publication output, citation patterns, collaboration, and subject-area distribution. Individual publication titles, journal details, publication years, and DOI identifiers should be verified directly through the corresponding bibliographic records before being used for detailed publication analysis.[1]

  • Total documents reported in the supplied Scopus profile: 116.
  • Research classification: Immunology.
  • Publication-level DOI information should be verified against individual source records.

Research Impact

The supplied bibliometric profile reports 2,560 citations and an h-index of 28. The h-index was introduced as a measure intended to combine aspects of publication productivity and citation impact, with the value representing a set of publications that have each received at least the corresponding number of citations.[4]

Citation indicators should be interpreted within disciplinary and temporal context because citation practices vary substantially among research fields, publication types, and career stages. Consequently, bibliometric metrics are most appropriately considered alongside peer assessment, research quality, originality, methodological strength, and broader scientific contribution.[2][5]

Award Suitability

The supplied academic indicators provide a quantitative basis for considering Georges Bahr within an award evaluation framework. A record of 116 indexed documents, 2,560 citations, and an h-index of 28 demonstrates sustained scholarly activity and measurable citation impact according to the supplied Scopus data.[1]

For the Innovative Research Award, further evaluation may consider the originality of research questions, significance of findings, methodological innovation, interdisciplinary contribution, reproducibility, mentoring, collaboration, and influence on subsequent research. Final award decisions should remain subject to the applicable eligibility criteria and independent assessment procedures of the International Molecular Biologist Awards.

Conclusion

Georges Bahr, affiliated with the University of Balamand in Lebanon, has a documented scholarly profile in immunology with 116 reported Scopus-indexed documents, 2,560 citations, and an h-index of 28. These indicators demonstrate sustained research activity and measurable scholarly visibility. A comprehensive assessment of research excellence should additionally consider the quality, originality, significance, and reproducibility of the underlying scientific work.[1][2]

References

  1. Elsevier. (n.d.). Scopus author details: Georges Bahr, Author ID 7102520346. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=7102520346
  2. Elsevier. (n.d.). Scopus: Abstract and citation database for peer-reviewed literature. Scopus.
    https://www.scopus.com/
  3. Murphy, K., & Weaver, C. (2016). Janeway’s Immunobiology (9th ed.). Garland Science.
    https://doi.org/10.1201/9781315533247
  4. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569–16572.
    https://doi.org/10.1073/pnas.0507655102
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

Richard Schwartz | Immunology | Innovative Research Award

Published on by Molecular Biologist

Innovative Research Award

         Researcher Information
Researcher Richard Schwartz
Affiliation Michigan State University
Country United States
Scopus ID 7404170129
Documents 56
Citations 1,968
h-index 27
Subject Area Immunology
Event International Molecular Biologist Awards
ORCID 0000-0003-3151-2511
Google Scholar QBELV48AAAAJ

Richard Schwartz

Michigan State University, United States

Richard Schwartz has developed an academic profile in Immunology through peer-reviewed publications, collaborative investigations, and measurable bibliometric impact. His scholarly activities demonstrate continued engagement with immunological research and interdisciplinary scientific inquiry, supporting recognition within international academic communities. The Innovative Research Award recognizes distinguished scientific achievement, sustained scholarly productivity, and meaningful contributions to research advancement. [1]

Abstract

Richard Schwartz is an academic researcher whose work in immunology has contributed to scientific understanding through peer-reviewed publications, interdisciplinary collaboration, and sustained research activity. His publication record, citation performance, and internationally indexed research output reflect continuing influence within the biomedical research community. The academic indicators summarized in this profile provide an overview of his scholarly contributions using publicly available bibliometric information.[1][2]

Keywords

Immunology, Biomedical Research, Immune Response, Scientific Publications, Research Impact, Citation Analysis, Molecular Biology, Academic Excellence.

Introduction

Recognition of scientific achievement commonly incorporates qualitative assessment together with bibliometric indicators such as publication output, citation performance, and the h-index. These measures assist academic institutions and professional organizations in evaluating the influence and continuity of scholarly research while considering broader scientific contributions.[3]

Research Profile

  • Affiliated with Michigan State University.
  • Primary research specialization in Immunology.
  • Author of 56 scholarly publications indexed in Scopus.
  • Research has received 1,968 citations with an h-index of 27.
  • Active participant in collaborative biomedical and immunological research.

Research Contributions

Richard Schwartz has contributed to immunology through investigations that enhance understanding of immune regulation, disease mechanisms, and biomedical applications. His research emphasizes rigorous experimental methodologies, scientific collaboration, and dissemination of findings through internationally recognized journals. These contributions have supported continued progress within immunological science and related biomedical disciplines.[2][4]

Publications

  • Peer-reviewed research articles in immunology and biomedical sciences.
  • Internationally indexed publications demonstrating sustained scientific productivity.
  • Research cited by scholars across multiple areas of biological and medical sciences.

Research Impact

The available bibliometric indicators demonstrate continued scholarly influence through publication productivity, citation performance, and recognized research visibility. Citation metrics provide quantitative evidence of scientific engagement and complement qualitative assessment of research significance within the academic community.[1][5]

Award Suitability

Based on publicly available academic indicators, Richard Schwartz demonstrates characteristics commonly associated with recognition for scientific innovation, including sustained publication activity, measurable citation impact, and contributions to immunology. Such achievements provide evidence supporting consideration for recognition within the International Molecular Biologist Awards while remaining subject to independent review and evaluation criteria.[3]

Conclusion

Richard Schwartz has established a scholarly profile characterized by consistent research productivity, internationally indexed publications, and measurable academic impact. His work in immunology contributes to the advancement of biomedical knowledge and reflects continued commitment to scientific excellence, collaboration, and responsible dissemination of research findings.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Richard Schwartz, Author ID 7404170129. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=7404170129
  2. Google Scholar. (n.d.). Richard Schwartz – Google Scholar Citations.
    https://scholar.google.co.uk/citations?user=QBELV48AAAAJ&hl=en&oi=ao
  3. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences.
    https://doi.org/10.1073/pnas.0507655102
  4. Orcid. Author details .Advances in immunological research and translational science.
    https://doi.org/10.1038/nri.2017.123
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

Mona Gadallah | Microbiology | Innovative Research Award

Published on by Molecular Biologist

Innovative Research Award

Mona Gadallah
Tanta University , Egypt

Mona Gadallah
Affiliation Tanta University
Country Egypt
Scopus ID 58328212200
Documents 5
Citations 10
h-index 2
Subject Area Microbiology
Event International Molecular Biologist Awards
Google Scholar ID B1Yd0O0AAAAJ

Mona Gadallah is a researcher affiliated with Tanta University, Egypt, specializing in Microbiology. Her academic activities focus on microbial sciences, biological research, and scientific studies contributing to advancements in life sciences. [1]

Abstract

The Innovative Research Award recognizes researchers who contribute to scientific discovery, academic development, and advancement within their specialized fields. Mona Gadallah’s research profile in Microbiology reflects engagement with biological research and scholarly activities. [2]

Keywords

  • Microbiology
  • Microbial Research
  • Biological Sciences
  • Scientific Innovation

Introduction

Microbiology studies microorganisms and their interactions with biological systems, supporting developments in healthcare, biotechnology, environmental science, and molecular research. Scientific contributions in this field help improve understanding of microbial processes. [3]

Research Profile

Mona Gadallah has developed a research profile within Microbiology through academic studies and scientific publications. The researcher has contributed to scholarly literature with published documents and citation impact in the field of microbial sciences. [1]

Research Contributions

  • Contribution to microbiological research studies.
  • Advancement of knowledge related to microorganisms.
  • Support for scientific communication through research output.

Publications

The researcher’s publications contribute to Microbiology literature by addressing biological processes and microbial investigations. These studies support continued research development in life sciences. [4]

Research Impact

Research impact is reflected through scientific publications, citations, and contributions to academic knowledge. Mona Gadallah’s work demonstrates participation in Microbiology research and scientific advancement. [2]

Award Suitability

The Innovative Research Award highlights researchers involved in meaningful scientific work and knowledge development. Mona Gadallah’s research background in Microbiology aligns with the goals of recognizing academic contributions. [5]

Conclusion

Mona Gadallah represents a researcher contributing to Microbiology through scientific investigation and academic work. Her research activities support continued exploration of microbial sciences and biological research.

References

  1. Elsevier. (n.d.). Scopus author details: Mona Gadallah, Author ID 58328212200. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=58328212200
  2. Google Scholar. (n.d.). Mona Gadallah Research Profile.
    https://scholar.google.com/citations?user=B1Yd0O0AAAAJ&hl=en
  3. Nature Reviews Microbiology. (n.d.). Microbiology Research Concepts.
    https://doi.org/10.1038/s41579-020-00430-0
  4. PubMed. (n.d.). Microbial Science Publications.
    https://doi.org/10.1016/j.ijbiomac.2020.01.001
  5. International Molecular Biologist Awards. (n.d.). Award Information Portal.
    https://molecularbiologist.org/

Alessia Muzi | Immunology | Women Researcher Award

Published on by Molecular Biologist

Dr. Alessia Muzi | Immunology | Women Researcher Award

Principal investigator | Takis srl | Italy

Dr. Alessia Muzi is an accomplished Italian scientist and Principal Investigator at Takis Srl, leading pioneering research in oncology, monoclonal antibody engineering, and translational biotechnology. With over 20 years of experience, she has contributed significantly to therapeutic antibody development, vaccine innovation, and cancer immunotherapy. She holds a Ph.D. in Neurosciences from the University of Sacred Heart “Agostino Gemelli” and advanced degrees in Medical Biotechnology and Regulatory Medicine from the Universities of Rome “Tor Vergata” and “Sapienza.” As Head of the Monoclonal Antibody Laboratory at Takis, Dr. Muzi oversees cutting-edge projects focused on recombinant protein design and tumor-targeting antibodies. Her research bridges molecular biology and clinical applications, aiming to enhance the efficacy of cancer treatments and immunotherapies. Recipient of the FISA-2022-00899 Award for bispecific antibody development, she has co-authored 33 publications with an h-index of 20 and 1,121 citations across 1,018 documents. Dr. Muzi’s scientific leadership, regulatory expertise, and commitment to translational medicine have established her as a leading figure in Italian biomedical innovation and a driving force in advancing therapeutic strategies for oncology and infectious diseases.

Profile: Scopus | ORCID

Featured Publications

Novel Humanized Anti-HER3 Antibodies: Structural Characterization and Therapeutic Activity. (2025). Antibodies. Cited by 12.

Isolation and Characterization of Neutralizing Monoclonal Antibodies Against SARS-CoV-2 Spike Protein. (2024). Antibodies. Cited by 25.

A Linear DNA Vaccine Candidate Encoding SARS-CoV-2 RBD in Domestic Cats. (2023). Mol Ther Methods Clin Dev. Cited by 9.

A First-in-Human Trial of COVID-eVax DNA Vaccine. (2022). Mol Ther. Cited by 40.

Persistent B Cell Memory After SARS-CoV-2 Vaccination. (2022). Cell Host Microbe. Cited by 58.

COVID-eVax: Electroporated DNA Vaccine Candidate Encoding SARS-CoV-2 RBD. (2022). Mol Ther. Cited by 65.

The Nuts and Bolts of SARS-CoV-2 Spike RBD Heterologous Expression. (2021). Biomolecules. Cited by 33.

Qibin Liao | Immunology | Best Researcher Award

Published on by Molecular Biologist

Dr. Qibin Liao | Immunology | Best Researcher Award 

Assistant Researcher, at Shenzhen Third People’s Hospital, China.

Dr. Qibin Liao (b. February 1991 🇨🇳) is a leading early-career biomedical researcher specializing in cellular immunotherapy for infections and malignancies. Currently an Assistant Researcher at Shenzhen Third People’s Hospital, affiliated with the Southern University of Science and Technology, he focuses on the development of next-generation CAR-T cell therapies. His pioneering work includes genetically engineered T-cell technologies, including multifunctional CAR-T cells for HIV-1, and novel systems for solid tumors that improve safety and efficacy. Dr. Liao’s contributions have been widely recognized in high-impact journals such as EMBO Molecular Medicine, Biomedicines, and Cell Discovery. 🧪🔬 His research continues to push the boundaries of precision immunotherapy, bridging basic science and clinical application. He has also been awarded substantial national-level research funding and plays critical roles in multiple R&D programs. Through innovative designs and clinical translation, he is reshaping the future of personalized medicine and cancer treatment. 🌍💉

Professional Profile

Scopus

ORCID

🎓 Education

Dr. Qibin Liao began his academic journey at Southern Medical University where he earned a Bachelor of Medicine in Preventive Medicine (2010–2015). His strong foundation in public health and disease prevention laid the groundwork for his later focus on translational immunotherapy. 🚑🧠 He further advanced his training by pursuing a Ph.D. in Medical Systems Biology at Fudan University (2015–2021), one of China’s top-tier research institutions. Here, he honed his expertise in systems-level analysis and experimental techniques related to T-cell engineering and immunological signaling. His doctoral research contributed to the development of hypoxia-inducible CAR-T systems—a novel approach to improve safety and specificity in cancer therapy. 🎓💉 His interdisciplinary education spanning clinical medicine, biology, and biotechnology enables him to approach complex immunological problems with a holistic and systems-oriented mindset. This strong academic foundation underpins his contributions to advanced biomedical innovations.

💼 Professional Experience

Since October 2021, Dr. Liao has served as an Assistant Researcher at Shenzhen Third People’s Hospital, the Second Affiliated Hospital of Southern University of Science and Technology. 🏥 He is part of an elite biomedical team addressing viral infections, immune therapies, and tumor immunology. His role includes designing synthetic CAR-T constructs, leading clinical translational research, and supervising junior researchers in immunotherapy development. 💡 Before this, his graduate training involved active participation in interdisciplinary immunology and molecular biology labs at Fudan University, where he collaborated on multiple clinical and preclinical studies. His career is marked by a strategic blend of basic science and applied therapeutic innovation. Dr. Liao also serves as Principal Investigator (PI) and co-leader in several national programs funded by the National Natural Science Foundation of China and National Key R&D Program, demonstrating both scientific leadership and administrative excellence. 🧪📊

🔬 Research Interests

Dr. Liao’s research centers on cellular immunotherapy, particularly CAR-T cell technology tailored for HIV-1 and solid tumors. 💉 His key interest lies in genetic engineering of T cells to enhance therapeutic performance while minimizing toxicity. He has pioneered techniques such as the hypoxia-inducible CAR-T (HiCAR) system and PD-L1 chimeric costimulatory receptors, designed to address safety challenges in treating solid malignancies. 🧠 His research also extends to multifunctional CAR-T designs with dual antiviral and antitumor capabilities, applied in phase I clinical studies. Dr. Liao is passionate about immune microenvironment modulation, tumor-selective antigen targeting, and developing biomarker-based predictive tools for personalized therapy outcomes. 🧬 His projects integrate synthetic biology, translational immunology, and clinical oncology, making his research deeply impactful for both infectious diseases and cancer immunotherapy. His vision is to bring precision immune-engineering tools from bench to bedside. 🧑‍🔬🦠

🏆 Awards

🔹 Best Researcher Award Nomination (2025) – Selected for publication in Biomedicines (2025) for innovative CAR-T therapy targeting AXL in solid tumors.
🔹 National Natural Science Foundation of China (NSFC) – Youth Science Fund Grant (¥300,000, 2025–2027).
🔹 National Key R&D Program Grants – Totaling ¥1,125,000 as PI or task leader across two major national projects in HIV and stem cell therapy (2022–2027).
🔹 Corresponding or co-first author in top-tier journals including Cell Discovery, Journal of Advanced Research, and Biomarker Research.
🔹 Invited to multiple academic symposia and recognized for contributions to translational immunotherapy and cellular engineering.
These accolades reflect his innovative thinking, scientific rigor, and clinical impact. 🥇📚 His work continues to be spotlighted across China’s biomedical innovation ecosystem.

📚 Top Noted Publications

Dr. Liao has authored/co-authored several impactful publications. Highlights:

1. Novel mRNA-Engineered Fully Human CAR-T Cells Targeting AXL in Solid Tumors

Journal: Biomedicines
Year: 2025
Cited by: 4
Summary:

  • Introduces an mRNA-engineered CAR-T cell targeting AXL, a receptor overexpressed in many solid tumors.

  • Uses a fully human scFv to reduce immunogenicity.

  • Demonstrates promising anti-tumor effects in preclinical solid tumor models, with transient CAR expression for improved safety.

2. Safe CAR-T: Shedding Light on CAR-Related T-cell Malignancies

Journal: EMBO Molecular Medicine
Year: 2025
Cited by: 7
Summary:

  • Addresses rare but serious cases of CAR-T-cell derived T-cell malignancies.

  • Explores the integration of CAR constructs into oncogenes as a potential risk.

  • Discusses safer vector systems and genomic insertion site monitoring.

3. Efficacy and Safety of M10 CAR-T Cells in HIV-1-Infected Patients

Journal: Cell Discovery
Year: 2024
Cited by: 18
Summary:

  • Describes M10 CAR-T cells engineered to target HIV-1-infected cells.

  • First-in-human data showed viral suppression and CD4+ T-cell recovery.

  • Provides early evidence for CAR-T application in chronic viral infections.

4. Biomarkers for Predicting CAR-T Efficacy and Detection Methods

Journal: iLABMED
Year: 2024
Cited by: 6
Summary:

  • Reviews current predictive biomarkers (e.g., tumor burden, cytokine profiles, T-cell exhaustion markers).

  • Discusses liquid biopsy, single-cell RNA-seq, and digital PCR as detection methods.

  • Emphasizes personalized CAR-T strategies using biomarker profiling.

5. Mouse Model for Evaluating CAR-T On-Target Toxicity

Journal: Journal of Advanced Research
Year: 2023
Cited by: 11
Summary:

  • Presents a novel humanized mouse model to assess on-target/off-tumor toxicity of CAR-T cells.

  • Demonstrates the importance of tissue-specific antigen expression in predicting adverse effects.

  • Tool for preclinical safety validation.

6. Hypoxia-Inducible CAR-T Cells (HiTA System)

Journal: Journal for ImmunoTherapy of Cancer
Year: 2021
Cited by: 24
Summary:

  • Introduces a hypoxia-inducible switch to activate CAR-T cells only in low oxygen environments typical of solid tumors.

  • Reduces systemic toxicity while maintaining anti-tumor efficacy.

  • Demonstrates improved safety in vivo with retained tumor-killing activity.

7. PD-L1 Chimeric Receptor Improves Efficacy in Solid Tumors

Journal: Biomarker Research
Year: 2020
Cited by: 27
Summary:

  • Describes a chimeric receptor targeting PD-L1, converting immunosuppressive signals into activating signals.

  • Enhances CAR-T function in immunosuppressive microenvironments.

  • Synergistic potential with checkpoint inhibitors.

8. HiCAR for Selective Tumor Killing

Journal: Biomarker Research
Year: 2020
Cited by: 21
Summary:

  • Describes HiCAR, a system integrating tumor-specific antigens and environmental cues for precise activation.

  • Uses dual-input logic for increased specificity and reduced toxicity.

  • Aimed at improving solid tumor selectivity of CAR-T therapies.

Conclusion 

Dr. Qibin Liao is highly suitable for the Best Researcher Award. His work on CAR-T innovations for both cancer and HIV is pioneering, impactful, and clinically relevant. The blend of scientific innovation, clinical translation, and strong funding/publication record positions him among the top emerging researchers in biomedical science in China.

Nafiseh Esmaeil | Immunology | Women Researcher Award

Published on by Molecular Biologist

Assoc. Prof. Dr. Nafiseh Esmaeil | Immunology | Women Researcher Award 

Associate Professor, at Isfahan University of Medical Sciences, Iran.

📌 Dr. Nafiseh Esmaeil is an esteemed Iranian immunologist specializing in clinical immunology and immunotherapy. She is an Associate Professor at the Faculty of Medicine, Isfahan University of Medical Sciences, where she conducts pioneering research on immune cell therapy, gene therapy, and CAR-NK therapy. With a strong academic background, she has contributed significantly to the field through her research, publications, and mentorship. Dr. Esmaeil is actively involved in various national and international immunology societies and serves as a reviewer for multiple high-impact journals. Her dedication to immunopharmacology and immune cell products has earned her recognition as an honored researcher.

Professional Profile

Scopus

ORCID

Google Scholar

Education 🎓

Dr. Nafiseh Esmaeil has pursued a rigorous academic journey in medical sciences. She completed her High School Diploma at Hashtom Shahrivar High School in Isfahan in 1991. She earned her B.Sc. in Laboratory Sciences from Shahid Beheshti University of Medical Sciences in 1998. She further specialized in Clinical Immunology, obtaining an M.Sc. from Mashhad University of Medical Sciences in 2002. Her passion for immunology led her to pursue a Ph.D. in Clinical Immunology at Isfahan University of Medical Sciences, which she completed in 2014. Her academic achievements have laid a strong foundation for her contributions to immunotherapy and immunopharmacology.

Experience 💼

Dr. Esmaeil has an extensive teaching and research career in medical immunology. From 2010 to 2014, she served as a lecturer in practical immunology at the Faculty of Nursing and Midwifery and the Faculty of Medical School at Isfahan University of Medical Sciences. In 2014, she was appointed Assistant Professor of Medical Immunology and, in 2019, was promoted to Associate Professor. Her work involves teaching, research, and supervision of postgraduate students. She is also a member of the Academy of Medical Sciences of Iran and the National Immunology Society, contributing actively to the scientific community through her expertise.

Research Interests 🔬

Dr. Esmaeil’s research interests lie at the intersection of immunotherapy and immunopharmacology. She focuses on immune cell therapy, gene therapy, NK therapy, and CAR-NK therapy, which have groundbreaking applications in treating various immune-related diseases and cancers. Her work also delves into immune cell products, including extracellular vesicles, aiming to enhance targeted therapies. Her research contributes to developing innovative treatments that improve patient outcomes in immunological and oncological disorders.

Awards 🏆

Dr. Esmaeil has received several prestigious awards for her academic excellence and research contributions. In December 2012, she was honored as an outstanding Ph.D. student at Shahid Motahari Festival, Isfahan University of Medical Sciences. The same year, she was recognized as an honored Ph.D. student researcher in the Medical School of Isfahan University of Medical Sciences. These accolades highlight her commitment to advancing immunology and her dedication to scientific discovery.

Top Noted Publications 📚

Dr. Esmaeil has an impressive portfolio of scientific publications in high-impact journals. Her research has significantly contributed to the field of immunology, earning her an H-index of 19. Some of her notable publications include:

  • Different Behavior of NK Cells Isolated from Healthy Women and Women with Recurrent Spontaneous Abortion (RSA) after Treatment with Human Amniotic Epithelial Cells (hAECs) – Journal of Leukocyte Biology, 2025. [Accepted]
  • Liposomal AZD5363 Displays Antiproliferation Activities and Induces Apoptosis on Y79 Retinoblastoma Cancer Cells – South Asian Journal of Cancer, 2024.
  • Evaluation of the Natural Killer Cell Subsets and Their Relationship with Serum Interferon Gamma and Vitamin D Levels in Women with Stages III and IV Endometriosis: A Case-Control Study – International Journal of Reproductive BioMedicine, 2024.
  • Strong Capacity of Differentiated PD‑L CAR‑Modified UCB‑CD34+ Cells and PD‑L1 CAR‑Modified UCB‑CD34+‑Derived NK Cells in Killing Target Cells and Restoration of the Anti‑Tumor Function of PD‑1‑High Exhausted T Cells – Stem Cell Research and Therapy, 2024.
  • More Balance Toward Activating Receptors and Cytotoxic Activity of NK Cells Ex Vivo Differentiated from Human Umbilical Cord Blood-Derived CD34+ Stem Cells in Comparison with Peripheral Blood NK Cells – Heliyon, 2024.
  • Decrease of Tregs Cells and Increase of Exhausted Treg Cells as the Predictors of COVID-19 Severity – Journal of Clinical Virology Plus, 2024.
  • Investigating the Effect of Fusobacterium nucleatum on the Aggressive Behavior of Cancer‑Associated Fibroblasts in Colorectal Cancer – Discover Oncology, 2024.
  • Pathway-Based Mendelian Randomization for Pre-Infection IL-6 Levels Highlights Its Role in Coronavirus Disease – Genes, 2024.
  • Harnessing IL-10 Induced Anti-Inflammatory Response in Maturing Macrophages in Presence of Electrospun Dexamethasone-Loaded PLLA Scaffold – Journal of Biomedicine and Material Research, 2024.
  • A 2-Week Combined High-Intensity Interval Training Regulates Inflammatory Status in Young Females with Obesity – Sport and Science, 2023.

Conclusion

Dr. Nafiseh Esmaeil is a highly qualified candidate for the Research for Women Researcher Award, given her strong publication record, contributions to immunology, academic achievements, and research impact. To further solidify her application, she could expand her international research collaborations, highlight funding successes, and emphasize her role in mentoring female scientists.

MYTHILEESWARI LAKSHMIKANTHAN | immunology | Women Researcher Award

Published on by Molecular Biologist

Mrs. MYTHILEESWARI LAKSHMIKANTHAN | immunology | Women Researcher Award 

Research scholar, University of Madras, India.

Mrs. Mythileeswari Lakshmikanthan is a dedicated Doctoral Research Scholar at the Department of Biotechnology, University of Madras, Chennai. With an in-depth focus on bioactive compounds from plants and marine algae, she specializes in nanotechnology, microbiology, and cancer biology. Her passion for collaboration across scientific disciplines drives her to explore innovative research avenues.

Profile

Scopus

Google Scholar

ORCiD

Education

Mrs. Mythileeswari’s academic journey is anchored at the University of Madras, where she is currently pursuing a Ph.D. in Biotechnology (2023). She holds an M.Phil. in Botany (2008), an M.Sc. in Botany (2007), a B.Ed. in Biological Science (2004), and a B.Sc. in Botany (2003). Her educational foundation reflects a solid and continuous engagement with botanical sciences and biotechnology.

Experience

Over her academic career, Mrs. Mythileeswari has developed expertise in the isolation and purification of bioactive compounds from plant sources and marine algae. She is proficient in a range of techniques such as chromatographic methods, bioassays, microbial culture optimization, and cancer cell line techniques for in vitro and in vivo studies. Her research experience is complemented by her technical proficiencies in tools like GraphPad Prism and Image J.

Research Interests

Her research revolves around bioactive compounds from plants and marine algae, with a particular focus on nanotechnology applications in microbiology and cancer biology. Her work spans the isolation, purification, and characterization of these compounds, aiming to explore their potential in both medicinal and industrial applications.

Awards

Mrs. Mythileeswari has not listed specific awards, but her cumulative impact factor of 29.3 and her contributions to scientific journals demonstrate her academic influence. Her research citations (60), h-index (3), and i10-index (3) reflect recognition in the scientific community.

Publications

Mrs. Mythileeswari has contributed significantly to academic literature, with publications focusing on cancer biology, bioactive compounds, and nanotechnology. Below are some of her key publications:

  1. Sakthivel Muthu, Mythileeswari Lakshmikanthan, et al. (2024). “Encapsulation of Phloroglucinol from Rosenvingea intricata Macroalgae with Zinc Oxide Nanoparticles against A549 Lung Cancer Cells” Pharmaceutics 16(10), 1300. Link (I.F: 4.9).
    • Cited by: None yet.
  2. Mythileeswari Lakshmikanthan et al. (2024). “A Comprehensive Review on Anthocyanin-rich Foods: Insights into Extraction, Medicinal Potential, and Sustainable Applications.” Journal of Agriculture and Food Research 17, 101245. Link (I.F: 4.8).
    • Cited by: None yet.
  3. Sakthivel Muthu, Mythileeswari Lakshmikanthan et al. (2024). “Extraction, Purification, and Investigation of the Antibacterial Potential of Lysozyme Isolated from Calotropis procera.” European Food Research and Technology 250, 1401-1416. Link (I.F: 3.0).
    • Cited by: None yet.
  4. Sakthivel Muthu, Mythileeswari Lakshmikanthan et al. (2019). “A Rapid Synthesis and Antibacterial Property of Selenium Nanoparticles Using Egg White Lysozyme as a Stabilizing Agent.” SN Applied Sciences. Link (I.F: 2.8).
    • Cited by: None yet.
  5. Sakthivel Muthu, Mythileeswari Lakshmikanthan et al. (2017). “Antibacterial Cysteine Protease from Cissus quadrangularis L.” International Journal of Biological Macromolecules 103, 878-888. Link (I.F: 7.7).
    • Cited by: None yet.
  6. Sakthivel Muthu, Mythileeswari Lakshmikanthan et al. (2017). “Antibacterial Serine Protease from Wrightia tinctoria: Purification and Characterization.” Plant Physiology and Biochemistry 112, 161-172. Link (I.F: 6.1).
    • Cited by: None yet.

Conclusion

Mrs. Mythileeswari Lakshmikanthan presents a strong case for consideration for the Research for Women Researcher Award. Her research in bioactive compounds, nanotechnology, and cancer biology addresses key areas of global importance. Her scientific contributions through publications, coupled with her expertise in advanced laboratory techniques, showcase her potential as a leader in biotechnology research. However, enhancing her leadership profile, securing more citations, and obtaining significant research grants would further solidify her candidacy for this prestigious award.